EyePoint (EYPT) Citigroup’s Biopharma Back to School Summit 2026 summary

Lead program overview and clinical trial updates

• DURAVYU, a sustained-release tyrosine kinase inhibitor, targets VEGF, PDGF, and JAK1 for back-of-eye diseases, with therapeutic levels maintained for at least six months per injection.

• Four phase III trials are ongoing: two in wet AMD (LUGANO and LUCIA) and two in DME (COMO and CAPRI), with DME trials fully enrolled and readouts expected in Q4 2027.

• LUGANO enrolled 432 wet AMD patients; the primary endpoint of non-inferiority in visual acuity was narrowly missed due to an unusual imbalance in vision loss events in the control arm.

• Extensive analysis showed no evidence that DURAVYU increases geographic atrophy or other adverse events compared to control.

• LUCIA, a larger and more international trial, is expected to read out in Q4, with confidence in a positive outcome based on secondary endpoints and statistical analyses.

Key trial results and commercial positioning

• Secondary endpoints in LUGANO showed strong safety, anatomical control, and a 42% reduction in injection burden, with most patients requiring four or fewer injections per year.

• Ad hoc analyses suggest that the primary endpoint miss was due to randomization luck, not drug efficacy, and that non-inferiority would likely be achieved under typical conditions.

• If LUCIA is positive, regulatory submission is planned for the first half of next year, with precedent for approval based on totality of data even if one pivotal trial is negative.

• Commercial adoption is expected to start with about a third of retina specialists' patients, especially those needing frequent injections, with potential for broader use as confidence grows.

• DME trials leverage the drug's JAK1 inhibition, with phase II data showing early efficacy and expectations for strong market penetration if approved.

Manufacturing, financials, and operational readiness

• Manufacturing is fully in-house at a state-of-the-art facility, with automation and scale-up supporting commercial launch and future growth.

• Cash position is strong, with $180 million on hand as of June, sufficient to fund operations through all major data readouts into Q4 2027.

• AI tools are being used selectively for efficiency, but data security is prioritized and wholesale adoption is cautious.

• Downstream analyses from LUGANO will be released before LUCIA results, providing further insight into trial outcomes.

• Leadership expresses confidence in the likelihood of positive LUCIA results and a clear path to regulatory approval and commercial success.